Latest1 information on COVID-19
©2022 Stanford Medicine
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Not Recruiting
Trial ID: NCT01289210
Purpose
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug
that stimulates the immune system) in combination with radiation therapy in treating patients
with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9
intratumoral injections of VTX-2337 over the course of 3 months.
Official Title
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
Stanford Investigator(s)
Manali Patel
Associate Professor of Medicine (Oncology)
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Eligibility
Major Inclusion Criteria:
- low grade B cell lymphoma
- 1 or more sites of disease appropriate for intratumoral injection
- measurable disease other than the injection site
- Performance Status of 1 or better
- Adequate bone marrow, renal and hepatic function
- No active autoimmune disease or systemic immunosuppressive drugs
- Life expectancy > 4 months
Exclusion Criteria:
- Known HIV
- Known brain metastases
- Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)
- Anticoagulation therapy other than 325mg QD ASA
- Significant cardiovascular disease
- Pregnant or nursing
Intervention(s):
drug: VTX-2337 plus radiotherapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Lori Richards
6507258589